Payment overview · 2025
General Payments
$35.32
2 reported records · 2 companies
Healthcare provider profile · identity verified
Daniel Matthew Bender, DO
Allopathic & Osteopathic Physicians|Family Medicine · RIVERTON, WY · NPI 1427585488
Verified facts
What the public records show
CMS Open Payments records show Daniel Matthew Bender, DO received $35.32 in general payments during 2025 across 2 reported records.
Novo Nordisk Inc accounted for 51.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.03 | 51.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.29 | 49.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $35.32 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
86 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
140 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 443 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 373 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 250 | 63 |
| Gabapentin | Gabapentin | 219 | 48 |
| Lisinopril | Lisinopril | 198 | 48 |
| Eliquis | Apixaban | 194 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 174 | 46 |
| Furosemide | Furosemide | 168 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 164 | 31 |
| Potassium Chloride | Potassium Chloride | 152 | 42 |
| Trazodone Hcl | Trazodone Hcl | 150 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 146 | 36 |
| Ozempic | Semaglutide | 140 | 27 |
| Jardiance | Empagliflozin | 129 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 32 |
| Omeprazole | Omeprazole | 122 | 35 |
| Simvastatin | Simvastatin | 115 | 24 |
| Meloxicam | Meloxicam | 114 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 36 |
| Losartan Potassium | Losartan Potassium | 104 | 28 |
| Alendronate Sodium | Alendronate Sodium | 102 | 27 |
| Carvedilol | Carvedilol | 91 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 18 |
| Metformin Hcl | Metformin Hcl | 88 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 21 |
| Bupropion Xl | Bupropion Hcl | 82 | 24 |
| Allopurinol | Allopurinol | 80 | 19 |
| Celecoxib | Celecoxib | 77 | 25 |
| Prednisone | Prednisone | 77 | 52 |
| Finasteride | Finasteride | 73 | 20 |
| Tramadol Hcl | Tramadol Hcl | 73 | 18 |
| Xarelto | Rivaroxaban | 73 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 22 |
| Spironolactone | Spironolactone | 70 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 63 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 18 |
| Januvia | Sitagliptin Phosphate | 61 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 61 | 19 |
| Metformin Hcl Er | Metformin Hcl | 57 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 52 | 22 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | suppressed |
| Chlorthalidone | Chlorthalidone | 49 | 14 |
| Alprazolam | Alprazolam | 48 | suppressed |
| Azithromycin | Azithromycin | 48 | 36 |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 31 |
| Diazepam | Diazepam | 47 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Mounjaro | Tirzepatide | 40 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 40 | 12 |
| Naltrexone Hcl | Naltrexone Hcl | 39 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 27 |
| Azelastine Hcl | Azelastine Hcl | 34 | 19 |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Humalog | Insulin Lispro | 32 | suppressed |
| Estradiol | Estradiol | 31 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Topiramate | Topiramate | 30 | 11 |
| Xifaxan | Rifaximin | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 13 |
| Xolair | Omalizumab | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 13 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Betaseron | Interferon Beta-1b | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Klayesta | Nystatin | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $35.32 · 2 records | Novo Nordisk Inc | TRELEGY ELLIPTA, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error